Dataset from A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia

VEGF Trap-Eye will be tested for safety and efficacy in patients with vision loss due to
choroidal neovascularization secondary to pathologic myopia. This will be a
placebo-controlled trial. 3 out of 4 patients will receive an injection of VEGF Trap-Eye into
the affected eye (and repeated injections if required), and 1 out of 4 patients will receive
a sham injection requiring no needle stick, but making the patient unaware of whether or not
he received active treatment.

Outcome of the two treatment groups will be compared after 24 weeks. From week 24, sham
patients may receive active treatment.

Total duration of the study will be 48 weeks.